Back to results
US 10,501,545 B2Granted
Anti-CLL-1 antibodies and methods of use
AssigneeGenentech, Inc.
InventorsRobert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
Claims31
An isolated anti-CLL-1 antibody, wherein the antibody comprises:
- (a) a CLL-1 binding domain, wherein the CLL-1 binding domain comprises six hypervariable regions (HVRs) as follows:
- (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 5, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 6, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 7, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 8, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 45 and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 10;
- or
- (ii) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 12, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 13, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 14, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 15, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 16 and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 17;
- or
- (iii) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 18, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 19, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 20, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 21, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 22 and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 23;
- or
- (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 24, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 25, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 26, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 27, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 28 and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 29;
- and
- (b) a CD3 binding domain, wherein the CD3 binding domain comprises six HVRs as follows:
- (i) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 74, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 75, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 76, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 71, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 72 and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 73;
- or
- (ii) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 74, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 80, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 76, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 77, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 78 and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 79;
- or
- (iii) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 74, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 80, an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 81, an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 77, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 78 and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 79.
54 more elements
An isolated anti-CLL-1 antibody, wherein the antibody comprises:
- (a) a CLL-1 binding domain, wherein the CLL-1 binding domain comprises:
- (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 31 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 30;
- or
- (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 33 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 32;
- or
- (iii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 34 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 32;
- or
- (iv) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 36 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 35;
- or
- (v) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 38 and the light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 37;
- or
- (vi) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 40 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 39;
- or
- (vii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 42 and the light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 41;
- or
- (viii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 46 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 32;
- and
- (b) a CD3 binding domain, wherein the CD3 binding domain comprises:
- (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 82 and the light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 83;
- or
- (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 84 and the light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 93;
- or
- (iii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 84 and the light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 85.
42 more elements
Dependencies are inferred from the claim text.